Prostate-Specific Antigen

Prostate-Specific Antigen, commonly abbreviated PSA, is a biomarker classified among tumor markers. Its entry provides the marker’s full name and abbreviation alongside the measurement information used to describe it.

This test requires a serum sample. Fasting is not required, so the test can be arranged without avoiding food beforehand. When booking or preparing for collection, confirm that the laboratory is measuring Prostate-Specific Antigen in serum and reporting the result in ng/mL.

Interpretation depends on which comparison is relevant. The page provides an overall reference range, an optimal range, and separate ranges for males and females; these should not be treated as interchangeable. Lower values are considered better for this biomarker, but a result should be read against the appropriate range rather than judged in isolation.

If the test is being arranged because of a medical condition or alongside other prostate-related testing, a clinician can help determine which reference range applies and how the result should be understood in context.

Interpret a result against the reference range printed on the same laboratory report, including its units. Laboratories may use different ranges and units, so a number is meaningful only in the context in which it was reported. The reference range describes the broader interval used for comparison, while the optimal range is tighter. For this marker, lower values are considered more favorable within the reference framework.

A value inside the reference range is not, by itself, proof that everything is normal, and a value outside it is not, by itself, a diagnosis. Results need to be considered alongside the clinical context and other relevant information. A single reading can provide only one point of information rather than a complete assessment. Out-of-range results, or results that raise concern, should be discussed with a clinician, particularly when a medical condition is involved.

For Prostate-Specific Antigen, a lower value is generally considered preferable. In trials that measured this marker directly, Saw Palmetto and Curcumin were associated with decreases in PSA, although the size of the change differed between interventions and studies.

Maca Root and Lycopene did not produce a significant change in PSA in the studies that measured them. These findings describe PSA specifically; they should not be interpreted as evidence that an intervention affects every prostate-related outcome.

Across these studies, PSA was generally rechecked after about 6 to 52.1 weeks. Differences in the interventions, study populations, and follow-up periods mean that results from one option should not be assumed to apply to another. PSA results also require clinical context, particularly when they are being used to evaluate a medical condition.